Unlocking a Combination Therapy for New Onset T1D

A new study is further assessing if a novel combination of drugs could help treat new onset type 1 diabetes University of Florida researchers are ready to launch a new clinical study to examine if a combination of two U.S Food and Drug Administration (FDA) approved drugs, antithymocyte globulin (ATG) and granulocyte colony stimulating factor […]

T1D Exercise Study – Participants Wanted!

Do you have type 1 diabetes? We are currently recruiting participants for an exercise intervention!!! The study will include group fitness classes at FITOLOGY and a series of tests before, during and after the intervention. The purpose of this study is to evaluate how exercise could improve blood sugar control of adults and adolescents with […]

Advancing a Key Artificial Pancreas Technology

Stable liquid glucagon developed by JDRF partner Xeris evaluated in first clinical study The JDRF Artificial Pancreas (AP) project is focused on accelerating the development of commercially-viable AP systems that better mimic the biological function of the pancreas and reduce the daily burden of managing type 1 diabetes (T1D). To achieve this goal, JDRF funds […]

JDRF FY2014 Annual Report Released

Thanks for making the 2013-2014 a great year for JDRF and the type one community in Central PA! Many exciting things have happened this year in T1D research, and the Central PA Chapter of JDRF raised $1.3 million to support this research. We couldn’t have done it without you! Check out the full Annual Report

Improving Beta Cell Health and Survival

JDRF-funded clinical study to test marketed drug to improve beta cell health and survival in T1D JDRF recently awarded a $2.1 million grant to Anath Shalev, M.D., director of the University of Alabama’s (UAB) Comprehensive Diabetes Center, to test the impact of a common blood pressure drug called verapamil on the health and survival of […]

Historic Progress for JDRF Encapsulation Research Program

Historic Progress for JDRF Encapsulation Research Program

First people with type 1 diabetes receive experimental encapsulated cell replacement therapies in clinical studies Two JDRF-funded partners have successfully implanted people with type 1 diabetes (T1D) with experimental encapsulated cell replacement therapies in clinical studies. These two programs are running in parallel and are evaluating two distinct encapsulation therapies. Encapsulated cell replacement therapy involves […]

It’s Time to Redefine Type 1 Diabetes

Last month, JDRF co-hosted a workshop where healthcare experts from government, nonprofit agencies and educational institutions discussed expanding the definition of Type 1 Diabetes (T1D) to recognize the earliest stages of human T1D before a person is clinically symptomatic. The benefits of the proposed system could include potentially faster drug development, identification of people living […]

Making the T1D Vaccine a Reality

Nanoparticle-based vaccine is designed to re-educate the immune system and halt the attack on the pancreas Over the last three years, Selecta Bioscience, a clinical stage biotechnology company, has been developing nanoparticles called Synthetic Vaccine Particle (SVP) as an immunotherapy for Type 1 diabetes (T1D) with support from JDRF and it was announced this week […]

JDRF-Funded Research Leads to Beta Cell Replacement Breakthrough

A new method for converting stem cells to beta cells could speed encapsulated cell replacement product development and research to cure type 1 diabetes Insulin therapy has long been the only method of treating type 1 diabetes (T1D), but a major breakthrough in producing replacement beta cells is bringing new hope that more effective, alternative […]

Unlocking Type 1 Diabetes Data

JDRF partners with Tidepool on data integration software for better type 1 diabetes management JDRF is partnering with the non-profit organization Tidepool to develop a new data integration tool for people with type 1 diabetes (T1D) who use insulin pumps, continuous glucose monitors, or blood glucose meters. The new tool at the center of the […]